Pharma spent 6.2 billion dollars on digital HCP marketing in 2025. 97 percent of it got ignored.
This is not a metric problem. It is a system problem, and it is not getting better with another email automation platform.
The Numbers Behind the 97 Percent
Open rates on traditional pharma email sit around 5 percent. Response rates around 1 percent. Click through rates around 2.25 percent. The most expensive prescription drugs in the world are being marketed through the same channel that pizza coupons use, with predictably worse engagement.
Inside the industry, 82 percent of pharma executives believe their digital outreach is working. Only 28 percent of HCPs agree. That 54 point confidence gap exists because the people who fund the budget are also the people defining what working means. Activity reports show high send volumes. Engagement dashboards show clicks. Almost nobody asks whether any of it changed prescribing behavior.
Why More Volume Is the Wrong Answer
The fix everyone reaches for is more volume. More channels. Another CRM migration. A new content management platform. None of it works because the problem is not delivery infrastructure.
The problem is relevance per interaction.
One email that knows what the HCP prescribed last month outperforms 50 generic blasts. One field visit prepared with behavioral data outperforms 20 visits with corporate slides. One piece of content built around a specific clinical question the HCP is actually working on outperforms an omnichannel campaign nobody asked for.
What Actually Works
Multi channel orchestrated approaches in oncology and immunology have produced documented engagement at fundamentally different orders of magnitude than email. Text messages to HCPs reach up to 98 percent open rates within minutes. WhatsApp medical literature delivery has produced 50 percent plus engagement rates compared to 6 percent for the same content as email attachments. Push notifications for safety updates produce 70 percent click rates compared to 3 percent for email alerts.
Same HCPs. Same inboxes. Completely different result, because the messages were earned rather than blasted.
The Compounding Cost of Being Ignored
There is a deeper economic problem buried in the 97 percent number. Every ignored email is not just one wasted impression. It actively trains the HCP to filter you harder next time. That makes the next ignored email cheaper to ignore than the last one.
This is negative compound interest, built one send at a time.
Most pharma marketing dashboards do not measure it because they cannot. The cost of an ignored email shows up two campaigns from now, not in this quarter.
The Regulatory Pressure Is Increasing
The FDA Office of Prescription Drug Promotion issued 40 untitled letters in a single day in September 2025, followed by approximately 80 warning letters one week later. The agency is filtering you out. The HCPs are filtering you out. And your own budget is filtering itself out, because ignored content is the most expensive content you will ever produce.
The Question Worth Asking
The honest question to ask your team this quarter is not how much you sent. It is how much was actually read.
If you cannot answer that question with first party data tied to actual prescribing behavior, your dashboard is measuring activity instead of impact. That is the gap most omnichannel strategies quietly fall apart inside.
